Drugmakers Still Oppose Medicare Talks Despite Reaching Deals

Top drugmakers have concluded talks with the Trump administration to slash the cost of certain expensive medicines under a Medicare price negotiation program, but the industry remains skeptical of the plan and its deals made behind closed doors.

Astellas Pharma Inc., AbbVie Inc., Bristol Myers Squibb Co., and GSK Plc are among the pharmaceutical companies that have shared or signaled that they have finalized talks with the US government involving their drugs selected for the Medicare Drug Price Negotiation Program.

The plan, established under former President Joe Biden, seeks to slash the cost of some of the ...